Pfizer blood cancer drug tops standard therapy for untreated patients

(Reuters) - Pfizer Inc said on Monday its cancer drug, Bosulif, was found superior to Novartis AG's Gleevec in a late-stage study on untreated patients with a form of blood and bone marrow cancer characterized by abnormal white blood cells production.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news